SOPH SOPHiA Genetics SA

Price (delayed)

$4.97

Market cap

$340.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$337.41M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and ...

Highlights
SOPHiA Genetics's revenue has increased by 21% YoY and by 5% QoQ
SOPH's gross profit is up by 19% year-on-year and by 4.9% since the previous quarter
SOPHiA Genetics's debt has surged by 107% YoY
SOPH's equity is down by 47% year-on-year and by 3.1% since the previous quarter

Key stats

What are the main financial stats of SOPH

SOPH stock price

How has the SOPHiA Genetics stock price performed over time
Intraday
3.97%
1 week
-2.17%
1 month
-6.05%
1 year
65.67%
YTD
6.42%
QTD
0.4%

Financial performance

How have SOPHiA Genetics's revenue and profit performed over time
Revenue
$81.18M
Gross profit
$54.62M
Operating income
-$72.15M
Net income
-$80.94M
Gross margin
67.3%
Net margin
-99.7%
The net income has contracted by 22% YoY and by 2.5% from the previous quarter
SOPHiA Genetics's revenue has increased by 21% YoY and by 5% QoQ
SOPH's gross profit is up by 19% year-on-year and by 4.9% since the previous quarter
SOPH's operating income is down by 13% YoY

Price vs fundamentals

How does SOPH's price correlate with its fundamentals

Growth

What is SOPHiA Genetics's growth rate over time

Valuation

What is SOPHiA Genetics stock price valuation
P/E
N/A
P/B
7.45
P/S
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.16
SOPHiA Genetics's EPS has decreased by 18% YoY
The P/B is 166% more than the 5-year quarterly average of 2.7 and 30% more than the last 4 quarters average of 5.5
SOPH's equity is down by 47% year-on-year and by 3.1% since the previous quarter
The P/S is 42% below the 5-year quarterly average of 6.9 but 3.3% above the last 4 quarters average of 3.9
SOPHiA Genetics's revenue has increased by 21% YoY and by 5% QoQ

Efficiency

How efficient is SOPHiA Genetics business performance
SOPHiA Genetics's ROE has plunged by 121% YoY and by 20% from the previous quarter
The ROA has declined by 22% year-on-year
The ROIC has grown by 19% YoY and by 6% from the previous quarter
SOPHiA Genetics's ROS has increased by 3.3% from the previous quarter

Dividends

What is SOPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SOPH.

Financial health

How did SOPHiA Genetics financials performed over time
SOPH's total assets is 41% greater than its total liabilities
The total liabilities has soared by 82% YoY but it has contracted by 4% from the previous quarter
The company's quick ratio fell by 38% YoY
SOPHiA Genetics's debt is 37% higher than its equity
SOPHiA Genetics's debt has surged by 107% YoY
SOPH's equity is down by 47% year-on-year and by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.